GSK reports its long-acting HIV PrEP tops Gilead's Truvada — again

GSK subsidiary ViiV Healthcare is notching another win on its scorecard for cabotegravir, the long-acting injectable it hopes can supplant Gilead’s daily pill for HIV prevention.